Pharvaris announces acceptance of abstracts for upcoming congresses, showcasing research on oral bradykinin B2 receptor antagonists and angioedema.

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and ...

The abstract, selected for oral communication, highlights the efficacy and tolerability of bexmarilimab , Faron's novel humanized anti-Clever-1 antibody, with no dose-limiting toxicities during dose ...

The Supreme Court of Georgia is testing out a new oral argument format in which parties are granted two minutes for uninterrupted opening arguments.

Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP ...

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) Mar. 25, 2025 8:00 AM ET CervoMed Inc ...

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) ...

A CLASS 2024 alumnus of the University of Santo Tomas (UST) College of Science won best oral presentation during the National University of Singapore Science Summer Institute (NUS SSI) 2024 at the NUS ...

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC ...

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

Format: Oral Presentation Date/Time: 18:30-19:30 Central European Time (CEST), July 11, 2024 Webcast Details Immutep will host a webcast to discuss the clinical data. A replay of the webcast will be ...